Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
- 1 June 2006
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 101 (3), 436-440
- https://doi.org/10.1016/j.ygyno.2005.10.036
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancerGynecologic Oncology, 2004
- Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group TrialJournal of Clinical Oncology, 2003
- Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assemblyAnti-Cancer Drugs, 2003
- Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian CancerJournal of Clinical Oncology, 2002
- Redefining the Target: Chemotherapeutics as AntiangiogenicsJournal of Clinical Oncology, 2001
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot studyInternational Journal of Gynecologic Cancer, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Paclitaxel (Taxol)New England Journal of Medicine, 1995